Project Description
MICRONUCLEUS TEST
Gentronix offers a range of screening options for the assessment of a test substance in the micronucleus test, and its potential to induce structural and numerical chromosomal damage.
SERVICE INFORMATION
Increases in micronuclei in the cytoplasm of interphase cells are indicative of either chromosome breaks (clastogens), or abnormal segregation of chromosomes during mitosis (aneugens). As such the in vitro micronucleus test can detect both the clastogenic and aneugenic modes of action for a test substance in a single endpoint. Furthermore, with modification to include FISH in the study design, this assay can be used to discriminate between these two mechanisms, helping support risk management and safety assessment.
Flow MNT
Conducted on a miniaturised format and using flow cytometry to score both micronuclei and cytotoxicity, the flow micronucleus assay provides a rapid prediction of the in vitro micronucleus test. The miniaturised format enables the study to be performed using far less test item than an OECD 487 study, and responsive delivery timelines.
MNT 96-well
A miniaturised version of a TK6 in vitro micronucleus test in which 2 treatment conditions are utilised in a 96-well microplate format. Micronucleus formation is assessed in mononuclear cell slides by microscopy, producing a highly predictive screen of the regulatory OECD 487 endpoint from minimal test item.
MNT OECD 487
Conducted in the same format at the OECD 487 guideline study, the study design can be tailored to a client’s requirements. With the help of our team of experts, we can work with you develop the most appropriate study design, whether TK6 cells or Primary Human Lymphocytes, varied metabolic activation or exposure conditions; delivering a predictive in vitro micronucleus test using a low quantity of test item.